Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 3, 2007, Pages

  Rademaker, Miriam T ^a   Charles, Chris J ^a   Richards, A Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cardiac output; Hormones; Renal function

Indexed keywords

ALDOSTERONE; ENDOTHELIN 1; NATRIURETIC FACTOR; UNCLASSIFIED DRUG; UROCORTIN; UROCORTIN 1; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DRUG EFFECT; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE; HEART OUTPUT; HEART PACING; HEART VENTRICLE OVERLOAD; NONHUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SODIUM EXCRETION; VASCULAR RESISTANCE;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT, LOW; CORTICOTROPIN-RELEASING HORMONE; ENDOTHELIN-1; EPINEPHRINE; FEMALE; HEART CONDUCTION SYSTEM; INFUSIONS, INTRA-ARTERIAL; KIDNEY; NOREPINEPHRINE; RENIN; SHEEP; VASCULAR RESISTANCE; VASOPRESSINS; VENTRICULAR FUNCTION, LEFT;

EID: 34548411382     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00377.2007     Document Type: Article

References (45)

1. Abdelrahman AM, Pang CC. Regional haemodynamic effects of urocortin in the anaesthetized rat. Eur J Pharmacol 466: 317-321, 2003.
2. Anker SD. Catecholamine levels and treatment in chronic heart failure. Eur Heart J 19: F56-F61, 1998.
3. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 101: 3697-3702, 2004.
4. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, Yellon DM, Latchman DS. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 275: 8505-8514, 2000.
5. Charles CJ, Espiner EA, Cameron VA, Richards AM. Hemodynamic, renal, and endocrine actions of ANF in sheep: effect of 24-h, low-dose infusions. Am J Physiol Regul Integr Comp Physiol 258: R1279-R1285, 1990.
6. Chen ZW, Huang Y, Yang Q, Li X, Wei W, He GW. Urocortin-induced relaxation in the human internal mammary artery. Cardiovasc Res 65: 913-920, 2005.
7. Coleman HN, Taylor RR, Pool PE, Whipple GH, Covell JW, Ross J Jr, Braunwald E. Congestive heart failure following chronic tachycardia. Am Heart J 81: 790-798, 1971.
8. Donald RA. Radioimmunoassay of corticotropin (ACTH). In: Handbook of Radioimmunoassay, edited by Abrahams G. New York: Dekker, 1977, p. 319-390.
9. Dunn PJ, Espiner EA. Outpatient screening for primary aldosteronism. Aust NZ Med J 6: 131-135, 1976.
10. Fitzpatrick MA, Nicholls MG, Espiner EA, Kram H, Bagshaw P, Yandle TG. Neurohumoral changes during the onset and offset of ovine heart failure: role of ANP. Am J Physiol Heart Circ Physiol 256: H1052-H1059, 1989.
11. Fitzpatrick MA, Rademaker MT, Frampton CM, Charles CJ, Yandle TG, Espiner EA, Ikram H. Hemodynamic and hormonal effects of renin inhibition in ovine heart failure. Am J Physiol Heart Circ Physiol 258: H1625-H1631, 1990.
12. Florio P, Arcuri F, Ciarmela P, Runci Y, Romagnoli R, Cintorino M, Di Blasio AM, Petraglia F. Identification of urocortin mRNA and peptide in the human endometrium. J Endocrinol 173: R9-R14, 2002.
13. Fukuda T, Takahashi K, Suzuki T, Saruta M, Watanabe M, Nakata T, Sasano H. Urocortin 1, urocortin 3/stresscopin, and corticotropin-releasing factor receptors in human adrenal and its disorders. J Clin Endocrinol Metab 90: 4671-4678, 2005.
14. Garcia-Villalon AL, Amezquita YM, Monge L, Fernandez N, Climent B, Sanchez A, Dieguez G. Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts. Br J Pharmacol 145: 490-494, 2005.
15. Goldstein DS, Feuerstein G, Izzo JL Jr, Kopin IJ, Keiser HR. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci 28: 467-475, 1981.
16. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081-1098, 1998.
17. Honjo T, Inoue N, Shiraki R, Kobayashi S, Otsui K, Takahashi M, Hirata K, Kawashima S, Yokozaki H, Yokoyama M. Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res 43: 131-138, 2006.
18. Ikeda K, Tojo K, Tokudome G, Ohta M, Sugimoto K, Tamura T, Tajima N, Mochizuki S, Kawakami M, Hosoya T. Cardiac expression of urocortin (Ucn) in diseased heart: preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases. Mol Cell Biochem 252: 25-32, 2003.
19. Lewis JG, Manley L, Whitlow JC, Elder PA. Production of a monoclonal antibody to cortisol: application to a direct enzyme-linked immunosorbent assay of plasma. Steroids 57: 82-85, 1992.
20. Liu CN, Yang C, Liu XY, Li S. In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms. Can J Physiol Pharmacol 83: 459-465, 2005.
21. Lun S, Espiner EA, Nicholls MG, Yandle TG. A direct radioimmunoassay for aldosterone in plasma. Clin Chem 29: 268-271, 1983.
22. Miki I, Seya K, Motomura S, Furukawa K. Role of corticotropin-releasing factor receptor type 2β in urocortin-induced vasodilation of rat aortas. J Pharm Sci 96: 170-176, 2004.
23. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 106: 383-388, 2004.
24. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K. Urocortin, a member of corticotropin-releasing factor family, in normal and diseased hearts. Am J Physiol Heart Circ Physiol 279: H3031-H3039, 2000.
25. Ogawa K, Shiozu H, Mizuno K, Ban M, Ito T, Satake T. Increased plasma cyclic nucleotide concentrations in congestive heart failure. Br Heart J 52: 524-529, 1984.
26. Okosi A, Brar BK, Chan M, D'Souza L, Smith E, Stephanou A, Latchman DS, Chowdrey HS, Knight RA. Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides 32: 167-171, 1998.
27. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol Heart Circ Physiol 272: H2115-H2122, 1997.
28. Pemberton CJ, Yandle TG, Charles CJ, Rademaker MT, Aitken GD, Espiner EA. Ovine brain natriuretic peptide in cardiac tissues and plasma: effects of cardiac hypertrophy and heart failure on tissue concentration and molecular forms. J Endocrinol 155: 541-550, 1997.
29. Rademaker MT, Cameron VA, Charles CJ, Espiner EA, Nicholls MG, Pemberton CJ, Richards AM. Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction. Am J Physiol Heart Circ Physiol 278: H731-H740, 2000.
30. Rademaker Cameron VA MT, Charles CJ, Richards AM. Integrated hemodynamic, hormonal and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 112: 3624-3632, 2005.
31. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Urocortin 3: hemodynamic, hormonal and renal effects in experimental heart failure. Eur Heart J 27: 2088-2098, 2006.
32. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 40: 1495-1505, 2002.
33. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Four-day urocortin-I administration has sustained beneficial hemodynamic, hormonal and renal effects in experimental heart failure. Eur Heart J 26: 2055-2062, 2005.
34. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur Heart J 26: 2046-2054, 2005.
35. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Nicholls MG, Richards AM. Natriuretic peptide responses to acute and chronic pacing in sheep. Am J Physiol Heart Circ Physiol 270: H594-H602, 1996.
36. Sadler WA, Lynsky CD, Gilchrist NL, Espiner EA, Nicholls MG. A sensitive assay for measuring plasma anti-diuretic hormone in man. NZ Med J 96: 959-962, 1983.
37. Sanz E, Fernandez N, Monge L, Climent B, Dieguez G, Garcia-Villalon AL. Relaxation by urocortin of rat renal arteries: effects of diabetes in males and females. Cardiovasc Res 58: 706-711, 2003.
38. Sanz E, Monge L, Fernandez N, Martinez MA, Martinez-Leon JB, Dieguez G, Garcia-Villalon AL. Relaxation by urocortin of human saphenous veins. Br J Pharmacol 136: 90-94, 2002.
39. Scarabelli TM, Pasini E, Stephanou A, Comini L, Curello S, Raddino R, Ferrari R, Knight R, Latchman DS. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. J Am Coll Cardiol 40: 155-161, 2002.
40. Schilling L, Kanzler C, Schmiedek P, Ehrenreich H. Characterization of the relaxant action of urocortin, a new peptide related to corticotropin-releasing factor in the rat isolated basilar artery. Br J Pharmacol 125: 1164-1171, 1998.
41. Shi M, Yan X, Ryan DH, Harris RB. Identification of urocortin mRNA antisense transcripts in rat tissue. Brain Res Bull 53: 317-324, 2000.
42. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol 169: 177-183, 2001.
43. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378: 287-292, 1995.
44. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 143: 508-514, 2004.
45. Yang C, Xu Y, Mendez T, Wang F, Yang Q, Li S. Effects of intravenous urocortin on angiotensin-converting enzyme in rats. Vasc Pharmacol 44: 238-246, 2006.